Proteomics in Medicine and Pharmacy

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: closed (31 December 2021) | Viewed by 5767

Special Issue Editors


E-Mail Website
Guest Editor
IRCCS SDN, Naples, Italy
Interests: quantitative proteomics; functional proteomics; protein–protein interactions; bioinformatics

E-Mail Website
Co-Guest Editor
Department of Movement Sciences and Wellness, University of Naples Parthenope, Naples, Italy
Interests: functional proteomics; differential proteomics; protein–protein interaction; aging; muscle physiology

E-Mail Website
Co-Guest Editor
Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Via S. Pansini 5, 80131 Napoli, Italy
Interests: biochemistry; molecular biology; cell biology; metabolomics; nanomedicine
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We are pleased to launch the Special Issue “Proteomics in Medicine and Pharmacy” covering all subjects and aspects of biomarker and drug discovery by proteomics-based approaches. We encourage you to submit up-to-date review and research articles concerning these topics in different biological systems, in vitro and in vivo.

Advances in proteomics have increased over the last decade, thus giving valuable contributions which range from basic research to biomedical and pharmaceutical applications. Proteomics have emerged as a valid methodology to analyze biological systems at molecular level. This discipline now permits not only an optimal generation of experimental data but also increased capabilities in data analysis for a successful biological interpretation. Today, several proteomics approaches (such as chemical, quantitative and functional proteomics, including the analyses of protein expression profiles, protein interaction networks and post-translational modifications) are widely carried out by clinicians and pharmaceutical companies.

In this scenario, proteomics helps to identify molecular mechanisms and characterize metabolic and cellular processes in several physiopathological conditions. Gaining insights into the molecular bases of healthy and diseased conditions (such as cancer, and cardiovascular, metabolic, neurological disorders) is just the first step of a bench-to-bedside process. Proteomic studies are highly relevant for the identification of valuable disease-specific biomarkers and the development of therapeutic strategies.

In this Special Issue, attention will be paid to the new trends in the applications of proteomics and coupled technologies (such as mass spectrometry, bioinformatics, nanotechnology) to medicine and pharmaceutical research.

Dr. Esther Imperlini
Guest Editor
Prof. Dr. Stefania Orrù
Dr. Armando Cevenini
Co-Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Quantitative proteomics
  • Protein–protein interaction network
  • Biomarker and drug discovery
  • Bioinformatics
  • Nanomedicine

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

13 pages, 356 KiB  
Review
Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics
by Paola Rognoni, Giulia Mazzini, Serena Caminito, Giovanni Palladini and Francesca Lavatelli
Medicina 2021, 57(9), 916; https://0-doi-org.brum.beds.ac.uk/10.3390/medicina57090916 - 31 Aug 2021
Cited by 2 | Viewed by 2045
Abstract
Amyloidoses are characterized by aggregation of proteins into highly ordered amyloid fibrils, which deposit in the extracellular space of tissues, leading to organ dysfunction. In AL (amyloid light chain) amyloidosis, the most common form in Western countries, the amyloidogenic precursor is a misfolding-prone [...] Read more.
Amyloidoses are characterized by aggregation of proteins into highly ordered amyloid fibrils, which deposit in the extracellular space of tissues, leading to organ dysfunction. In AL (amyloid light chain) amyloidosis, the most common form in Western countries, the amyloidogenic precursor is a misfolding-prone immunoglobulin light chain (LC), which, in the systemic form, is produced in excess by a plasma cell clone and transported to target organs though blood. Due to the primary role that proteins play in the pathogenesis of amyloidoses, mass spectrometry (MS)-based proteomic studies have gained an established position in the clinical management and research of these diseases. In AL amyloidosis, in particular, proteomics has provided important contributions for characterizing the precursor light chain, the composition of the amyloid deposits and the mechanisms of proteotoxicity in target organ cells and experimental models of disease. This review will provide an overview of the major achievements of proteomic studies in AL amyloidosis, with a presentation of the most recent acquisitions and a critical discussion of open issues and ongoing trends. Full article
(This article belongs to the Special Issue Proteomics in Medicine and Pharmacy)
20 pages, 409 KiB  
Review
Secretome Proteomic Approaches for Biomarker Discovery: An Update on Colorectal Cancer
by Armando Cevenini, Stefania Orrù and Esther Imperlini
Medicina 2020, 56(9), 443; https://0-doi-org.brum.beds.ac.uk/10.3390/medicina56090443 - 31 Aug 2020
Cited by 9 | Viewed by 3066
Abstract
Searching for new cancer-related biomarkers is a key priority for the early detection of solid tumors, such as colorectal cancer (CRC), in clinically relevant biological fluids. The cell line and/or tumor tissue secretome represents a valuable resource for discovering novel protein markers secreted [...] Read more.
Searching for new cancer-related biomarkers is a key priority for the early detection of solid tumors, such as colorectal cancer (CRC), in clinically relevant biological fluids. The cell line and/or tumor tissue secretome represents a valuable resource for discovering novel protein markers secreted by cancer cells. The advantage of a secretome analysis is the reduction of the large dynamic range characterizing human plasma/serum, and the simultaneous enrichment of low abundance cancer-secreted proteins, thereby overcoming the technical limitations underlying the direct search in blood samples. In this review, we provided a comprehensive overview of recent studies on the CRC secretome for biomarker discovery, focusing both on methodological and technical aspects of secretome proteomic approaches and on biomarker-independent validation in CRC patient samples (blood and tissues). Secretome proteomics are mainly based on LC-MS/MS analyses for which secretome samples are either in-gel or in-solution trypsin-digested. Adequate numbers of biological and technical replicates are required to ensure high reproducibility and robustness of the secretome studies. Moreover, another major challenge is the accuracy of proteomic quantitative analysis performed by label-free or labeling methods. The analysis of differentially expressed proteins in the CRC secretome by using bioinformatic tools allowed the identification of potential biomarkers for early CRC detection. In this scenario, this review may help to follow-up the recent secretome studies in order to select promising circulating biomarkers to be validated in larger screenings, thereby contributing toward a complete translation in clinical practice. Full article
(This article belongs to the Special Issue Proteomics in Medicine and Pharmacy)
Back to TopTop